Entropy Neurodynamics Limited Asset Resilience Ratio
Entropy Neurodynamics Limited asset resilience ratio. Entropy Neurodynamics Limited (ENP) has an Asset Resilience Ratio of 70.81% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Entropy Neurodynamics Limited liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Entropy Neurodynamics Limited (2024–2025)
Asset resilience ratio of Entropy Neurodynamics Limited from 2024 to 2025. This chart shows how Entropy Neurodynamics Limited's Asset Resilience Ratio has changed over time. Read debt load of Entropy Neurodynamics Limited for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Entropy Neurodynamics Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Entropy Neurodynamics Limited balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$6.43 Million | 70.81% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$6.43 Million | 70.81% |
Asset Resilience Insights
- Very High Liquidity: Entropy Neurodynamics Limited maintains exceptional liquid asset reserves at 70.81% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Entropy Neurodynamics Limited Industry Peers by Asset Resilience Ratio
Compare Entropy Neurodynamics Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Sinocelltech Group Ltd
SHG:688520 |
Biotechnology | 5.27% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 1.75% |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS |
Biotechnology | 78.33% |
|
GH Research PLC
NASDAQ:GHRS |
Biotechnology | 4.73% |
Entropy Neurodynamics Limited Asset Resilience Ratio by Year (2024–2025)
Entropy Neurodynamics Limited asset resilience ratio by year from 2024 to 2025. The table below shows the annual Asset Resilience Ratio data for Entropy Neurodynamics Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 45.42% | AU$3.03 Million ≈ $2.14 Million |
AU$6.66 Million ≈ $4.71 Million |
-26.64pp |
| 2024-06-30 | 72.06% | AU$5.37 Million ≈ $3.80 Million |
AU$7.45 Million ≈ $5.27 Million |
-- |
About Entropy Neurodynamics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more